The momentum building behind the development of novel therapeutics for genetic neuromuscular disorders, exemplified by periodic paralysis, is driven by a confluence of scientific breakthroughs, increased patient advocacy, and supportive regulatory frameworks worldwide. The fundamental understanding of the pathology has matured significantly, moving beyond simple symptomatic management to...